ERBB2 and non-small cell lung carcinoma: While a number of ADC are in the early stages of clinical development for NSCLC therapy and a few are in late-stage development or pending regulatory approval, only two ADC are currently approved for NSCLC: trastuzumab deruxtecan (T-DXd) for unresectable HER2-positive solid tumors including NSCLC and telisotuzumab vedotin (EMRELISTM), which recently received accelerated FDA approval for NSCLC with high C-met overexpression (23, 24).